Welcome to Decipher GRIDTM

We believe Decipher GRID is the largest shared, clinically-annotated genomic expression database in urologic cancer

Researchers and Physicians

Access Decipher GRID

Enhanced research through individualized genomic insights
learn more
Researchers and Physicians

See the Network

Find a GRID center near you

Make a Difference

If Decipher was ordered for you by your doctor, learn how you can contribute to ongoing cancer research
learn more

Decipher GRID in the News

GenomeDx’s Decipher Platform Utilizes Gene Expression Signatures to Predict Lymph Node Metastasis in Bladder Cancer Patients

Study Published in The Journal of Urology

San Diego, June 14, 2016 – GenomeDx Biosciences today announced that its Decipher GRIDTM platform was used to develop and validate a novel genomic signature, known as KNN51, for the prediction of lymph node involvement at the time of radical cystectomy in patients with muscle-invasive bladder cancer (MIBC).

read more

GenomeDx’s Decipher GRIDTM and Decipher® Tests to be Featured in Multiple Presentations at ASCO 2016

San Diego – May 23, 2016 – GenomeDx Biosciences today announced that four presentations featuring Decipher Genomics Resource Information Database (Decipher GRIDTM) and Decipher® Tests in Prostate Cancer will be presented at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting held June 3-7 in Chicago.

The abstract titled “Development and Validation of Genomic Signature that Predicts ADT Treatment Failure,” was chosen to be discussed at the Poster Discussion Session,

read more

GenomeDx’s Decipher Platform Identifies Gene Expression Associated with Resistance to Chemotherapy Treatment in Bladder Cancer

Study Presented at American Urologic Association 2016 Annual Meeting

San Diego, May 9, 2016 – GenomeDx Biosciences today announced that its Decipher® platform was used to evaluate molecular subtypes associated with resistance to platinum-based neoadjuvant chemotherapy (NAC) in patients with muscle-invasive bladder cancer (MIBC), supporting the potential use of a genomic signature to guide patient therapy.

read more